Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Dexcom (DXCM) Operating Expenses (2016 - 2026)

Dexcom has reported Operating Expenses over the past 17 years, most recently at $495.0 million for Q1 2026.

  • Quarterly Operating Expenses rose 8.72% to $495.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.9 billion through Mar 2026, up 5.3% year-over-year, with the annual reading at $1.9 billion for FY2025, 2.82% up from the prior year.
  • Operating Expenses was $495.0 million for Q1 2026 at Dexcom, up from $469.7 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $495.0 million in Q1 2026 and troughed at $346.7 million in Q3 2022.
  • The 5-year median for Operating Expenses is $441.8 million (2024), against an average of $435.7 million.
  • Year-over-year, Operating Expenses decreased 11.89% in 2022 and then rose 20.51% in 2023.
  • A 5-year view of Operating Expenses shows it stood at $415.9 million in 2022, then grew by 5.72% to $439.7 million in 2023, then increased by 6.19% to $466.9 million in 2024, then rose by 0.6% to $469.7 million in 2025, then rose by 5.39% to $495.0 million in 2026.
  • Per Business Quant, the three most recent readings for DXCM's Operating Expenses are $495.0 million (Q1 2026), $469.7 million (Q4 2025), and $488.9 million (Q3 2025).